New drug corresponding disease

Showing 61–72 of 201 results

  • Acromegaly , Acromegaly

    Octreotide

    【Product name】Sandostatin, ANDOSTATIN

    [English common name]Octreotide

    [Chinese common name]Octreotide

    [English name]CCRIS 8708, L-Cysteinamide, UNII-75R0U2568I, SMS 201-995, L-Cysteinamide, 

    [Chinese other name]

    [indications]
    Octreotide acetate:
    1. Emergency treatment of esophageal-gastric varices bleeding caused by cirrhosis, combined with special treatment (such as endoscopic sclerotherapy).
    2. Alleviate the symptoms and signs associated with gastrointestinal pancreatic endocrine tumors. There is sufficient evidence that octreotide is effective against the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors, etc., octreotide is about 50% effective against the following tumors.
    (1) Gastrinoma/Zollinger-Ellison Syndrome (usually in combination with a selective H2 receptor antagonist, and an antacid may be added as appropriate).
    (2) Islet tumors (for the prevention of hypoglycemia before the operation of islet tumors, maintaining normal blood sugar).
    (3) Growth hormone releasing factor tumor. Treatment with octreotide acetate only reduces symptoms and signs, but does not cure.
    Octreotide acetate microspheres for injection: This product is used forAcromegalyFor the treatment of the following acromegaly patients: after subcutaneous injection of standard dose of Shan Ning, the condition is fully controlled; patients who are not suitable for surgery, radiotherapy or treatment, or in the potential reaction stage before radiotherapy is fully effective Patient. Patients with gastrointestinal pancreatic endocrine tumors associated with functional gastrointestinal pancreatic endocrine tumor-related symptoms have been adequately controlled by subcutaneous injection of Shan Ning. Carcinoid with the characteristics of carcinoid syndrome. Vasoactive intestinal peptide tumor. Glucagonoma. Gastrinoma / Zhuo-Ai syndrome. Insulinoma (for prevention and maintenance of preoperative hypoglycemia). Growth hormone releasing factor adenoma.
    Octreotide acetate for injection:
    1. Emergency treatment of esophageal-gastric varices bleeding caused by cirrhosis, combined with special treatment (such as endoscopic sclerotherapy).
    2. Prevention of postoperative complications of the pancreas.
    3. Alleviate the symptoms and signs associated with gastrointestinal endocrine tumors. There is evidence that this product is effective against the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors; glucagonoma. This product has an effective rate of about 50% for the following tumors (there are limited cases of treatment with this product to date): gastrinoma/Zollinger-Ellison syndrome. Islet tumor. Growth hormone releasing factor tumor.
    4. Patients with acromegaly who have failed surgery or radiation therapy or dopamine agonist therapy can control symptoms and reduce the concentration of growth hormone (GH) and auxin medium C.
    Octreotide acetate injection:
    1. Emergency treatment of esophageal-gastric varices bleeding caused by cirrhosis, combined with special treatment (such as endoscopic sclerotherapy).
    2. Alleviate the symptoms and signs associated with gastrointestinal pancreatic endocrine tumors. There is sufficient evidence that octreotide is effective against the following tumors: carcinoid tumors with carcinoid syndrome; VIP tumors, etc., octreotide is about 50% effective against the following tumors.
    (1) Gastrinoma/Zollinger-Ellison Syndrome (usually in combination with a selective H2 receptor antagonist, and an antacid may be added as appropriate).
    (2) Islet tumors (for the prevention of hypoglycemia before the operation of islet tumors, maintaining normal blood sugar).
    (3) Growth hormone releasing factor tumor. Treatment with octreotide acetate only reduces symptoms and signs, but does not cure.

    【Dosage】
    Octreotide acetate:
    1, esophageal - gastric varices bleeding continuous intravenous infusion of 0.025 mg / hour. It can be treated for up to 5 days and can be diluted with physiological saline or diluted with glucose solution.
    2, prevention of complications after pancreatic surgery 0.1 mg subcutaneous injection, 3 times a day, continuous treatment for 7 days, the first injection should be performed at least 1 hour before surgery.
    3, the initial dose of gastrointestinal pancreatic endocrine tumor is 0.05 mg subcutaneous injection, one to two times a day, and then gradually increase the dose to 0.2 mg according to tolerance and efficacy, three times a day.
    4. The initial dose of acromegaly is 0.05-0.1 mg subcutaneously, once every 8 hours, and then adjusted according to monthly assessment of circulating GH concentration, clinical response and tolerability.
    Octreotide Acetate Microspheres for Injection: This product can only be administered by deep injection into the buttocks muscle, but never by intravenous injection. If you penetrate the blood vessel, you need to change the injection site. Repeated injections should take turns to select different hip muscle injections on the left or right side. Acromegaly is recommended for patients who have complete control of the standard dose of subcutaneous injection of Shan Ning. The recommended initial dose of this product is 20 mg, administered once every 4 weeks for a total of 3 months. Treatment can begin 1 day after the last subcutaneous injection of Shan Ning. Thereafter the dose should be based on the concentration of serum GH and growth factor C (IGF-1) as well as clinical signs and symptoms. If clinical signs and symptoms and biochemical parameters (GH and IGF-1) are not fully controlled (GH > 2.5 ug/L) after 3 months, the dose should be increased to 30 mg once every 4 weeks.
    Octreotide acetate for injection:
    1. Esophagus - bleeding of gastric varices. Continuous intravenous infusion of 0.025 mg / hour. It can be treated for up to 5 days and can be diluted with physiological saline or diluted with glucose solution.
    2. Prevention of complications after pancreatic surgery. 0.1 mg subcutaneously, 3 times a day for 7 days, the first injection should be performed at least 1 hour before surgery.
    3. gastrointestinal pancreatic endocrine tumors. The initial dose is 0.05 mg subcutaneously, one to two times a day, and then gradually increased to 0.2 mg three times a day according to tolerance and efficacy.
    4. Acromegaly. The initial dose is 0.05-0.1 mg subcutaneously, once every 8 hours, and then adjusted according to monthly assessment of circulating GH concentration. Clinical response and tolerability.
    Octreotide acetate injection:
    1. Esophagus-gastric varices bleeding first 0.1mg intravenous bolus (5 minutes), then 0.6mg dissolved in 5% glucose 500ml, continuous intravenous infusion through the infusion pump at 50μg / hour, 12 hours once . Treat for up to 5 days.
    2. The initial amount of gastrointestinal pancreatic endocrine tumor is 0.05 mg subcutaneous injection, one to two times a day. The dose can be gradually increased to 0.2 mg three times a day based on tolerance and efficacy (clinical response, hormone concentration secreted by the tumor). In some cases, larger doses may be used. The maintenance amount should be based on individual differences. After the clinical symptoms and laboratory tests showed no improvement, the medication should not exceed one week.

    [Storage]
    Octreotide acetate: shading, sealed, stored in a cold place (2-10 ° C).
    Octreotide acetate microspheres for injection: sealed and stored in a cool place.
    Octreotide acetate for injection: sealed.
    Octreotide acetate injection: shading, sealed, stored in a cold place (2-10 ° C).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Chronic lymphocyte leukemia

    Obiquitizumab

    【Product name】Gazyva

    [English common name]Obinutuzumab

    [Chinese common name]Obiquitizumab

    [English name]Ga101

    [Chinese other name]

    [indications]Chronic lymphocytic leukemia (CLL)

    【Dosage】
    Gazyvaro is a concentrate that can be made into an intravenous infusion solution and for more than a few hours. Gazyvaro treatment is given in six or eight cycles, each cycle lasting.
    21 or 28 days.
    For CLL, a 28 day period is used. A dose of 100 mg of GasyValo was administered on the first day of the first cycle.
    Under the close supervision of an experienced doctor, he should monitor patient infusion related conditions.
    reaction. If the patient does not take any medication, a second dose of 900 mg can be given on the same day.
    reaction. If the reaction related to the infusion, the first dose of 100 mg, the second dose should be
    Delay until the second day. A further dose of 1000 mg was then administered on days 8 and 15 of the first cycle. in order to
    For the remaining 5 cycles, GayyVro 1000 mg is given only on day 1.
    For FL, a dose of Gazyvaro 1000 mg was administered on days 1, 8, and 15 of the first 21 or 28 days of treatment.
    cycle. For the remaining cycles, the dose is given only on day 1. For patients who respond to treatment,
    May continue to receive Gazavar every two months for up to two years, as long as they benefit
    From it. Patients can also take other medications to prevent infusion-related reactions and other side effects.

    [Storage]It can be stored at 2 to 8 ° C for up to 24 hours.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Chronic myeloid leukemia

    Olfazumab

    【Product name】Arzerra

    [English common name]Ofatumumab

    [Chinese common name]Olfazumab

    [English name]

    [Chinese other name]

    [indications]Chronic lymphocytic leukemiaCD20 positive relapse or refractory.

    [Usage and Dosage] Once a week, such as ofatumumab (genetic recombination) and intravenous infusion of 2000 mg, the eighth repeated administration, the second and subsequent 300 mg for the first time in adults. The eighth dose was administered from 4 to 5 weeks, and the intravenous infusion of 2000 mg was performed once every four weeks, and the administration was repeated until after 12 days.

    [Storage] Store and transport cold storage (2 ° C – 8 ° C).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Melanoma

    Willofini

    【Product name】Zelboraf

    [English common name]Vemuranfenib

    [Chinese common name]Willofini

    [English name]Vemurafenib

    [Chinese other name]Virofini

    [indications]Zelboraf is a kinase inhibitor suitable for unresectable or metastaticMelanomaTreatment of patients with BRAFV600E mutations is tested with an FDA-approved test.

    【Dosage】2 times a day, 2 capsules each time.
    Take it every 12 hours, with or without meals.

    [Storage] Store in original packaging to protect it from moisture.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • asthma

    Montelukast sodium

    【Product name】KIPRES, MONTELUKAST, SINGULAIR

    [English common name]Montelukast Sodium

    [Chinese common name]Montelukast sodium

    [English name]

    [Chinese other name]

    [indications]
    Montelukast sodium tablets: This product is suitable for adults aged 15 and over.asthmaPrevention and long-term treatment, including prevention of asthma symptoms during the day and night, treatment of asthma patients who are sensitive to aspirin, and prevention of exercise-induced bronchoconstriction. This product is suitable for alleviating the symptoms caused by allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in adults aged 15 and over).
    Montelukast sodium chewable tablets: This product is suitable for the prevention and long-term treatment of asthma in children aged 2 to 14 years, including prevention of asthma symptoms during the day and night, treatment of aspirin-sensitive asthma patients and prevention of exercise-induced bronchoconstriction. This product is suitable for alleviating the symptoms caused by allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in children aged 2 to 14 years).
    Montelukast sodium granules: This product is suitable for the prevention and long-term treatment of asthma in children over one year old, including prevention of asthma symptoms during the day and night, treatment of aspirin-sensitive asthma patients and prevention of exercise-induced bronchoconstriction. This product is suitable for alleviating the symptoms caused by allergic rhinitis (seasonal allergic rhinitis and perennial allergic rhinitis in children aged 2 to 5 years old).

    【Dosage】
    Montelukast sodium tablets: once a day, one tablet each time (10 mg). Asthmatic patients should take it before going to bed. Patients with allergic rhinitis can take it when needed according to their own conditions.
    Patients with both asthma and allergic rhinitis should be given once a night. Adult patients with asthma and/or allergic rhinitis 15 years and older are administered once daily for 10 mg each time.
    General advice
    The therapeutic effect was evaluated by the asthma control index, and the efficacy of the product appeared within one day of the drug administration. This product can be taken with food or served separately. Patients should be advised to take it regardless of asthma control or deterioration.
    Older patients, patients with renal insufficiency, patients with mild to moderate liver damage, and patients of different genders do not need to adjust the dose.
    Relationship between montelukast sodium tablets and other asthma treatment drugs
    This product can be added to the patient's existing treatment plan.
    Reduce the dose of the combined medication:
    Bronchodilator
    Asthma patients who can not effectively control bronchodilator alone can be added to the treatment plan. Once there is obvious clinical response (usually after the first dose), the bronchodilator can be used according to the patient's tolerance. The dose is reduced.
    Inhaled corticosteroids
    For patients with asthma who receive inhaled corticosteroids, the dose of glucocorticoids can be appropriately reduced according to the patient's tolerance. It should be gradually reduced under the guidance of a physician. Some patients can gradually reduce the amount until inhaled glucocorticoids are completely discontinued. However, this product should not be used to suddenly replace inhaled corticosteroids.
    Montelukast sodium chewable tablets: once daily. Asthmatic patients should take it before going to bed. Patients with allergic rhinitis can take the medicine according to their own circumstances.
    Patients with both asthma and allergic rhinitis should be given once a night.
    Children aged 6 to 14 years with asthma and / or allergic rhinitis once a day, one tablet at a time (5mg).
    Children from 2 to 5 years old with asthma and/or allergic rhinitis once daily, one tablet at a time (4 mg).
    General advice
    The therapeutic effect was evaluated by the asthma control index, and the efficacy of the product appeared within one day of the drug administration. This product can be taken with food or served separately. Patients should be advised to take it regardless of asthma control or deterioration.
    There is no need to adjust the dose for patients with renal insufficiency, patients with mild to moderate liver damage, and patients of different genders.
    The relationship between this product and other asthma treatment drugs
    This product can be added to the patient's existing treatment plan.
    Reduce the dose of the combined drug:
    Bronchodilator
    In asthma patients who cannot be effectively controlled with bronchodilator alone, this product can be added to the treatment regimen. Once there is a clinical response (usually after the first dose), the dose of bronchodilator can be reduced according to the patient's tolerance. .
    Inhaled corticosteroids
    For patients with asthma who receive inhaled corticosteroids, the dose of glucocorticoids can be appropriately reduced according to the patient's tolerance. It should be gradually reduced under the guidance of a physician. Some patients can gradually reduce the amount until inhaled glucocorticoids are completely discontinued. However, this product should not be used to suddenly replace inhaled corticosteroids or as directed by your doctor.
    Montelukast sodium granules: once daily. Asthmatic patients should take it before going to bed. Patients with allergic rhinitis can take the medicine according to their own circumstances.
    Patients with both asthma and allergic rhinitis should be given once a night.
    Asthma patients from 1 to 2 years old once a day, one bag at a time.
    Asthma patients aged 2 to 5 years and/or patients with allergic rhinitis between the ages of 2 and 5 years.
    Take 4mg of oral granules a day.
    Oral granules
    This product can be taken directly, mixed with a spoonful of soft or soft food (such as applesauce), or dissolved in a teaspoon of room temperature or cold infant formula or breast milk. The bag can only be opened when taken. Take all doses (within 15 minutes) immediately after opening the bag. This product, mixed with food, infant formula or breast milk, can no longer be stored until the next time. This product should not be dissolved in other liquids other than infant formula or breast milk. However, you can drink water after taking the medicine.
    General advice
    The therapeutic effect was evaluated by the asthma control index, and the efficacy of the product appeared within one day of the drug administration. This product can be taken with food or served separately. Patients should be advised to take it regardless of asthma control or deterioration.
    There is no need to adjust the dose for patients with renal insufficiency, patients with mild to moderate liver damage, and patients of different genders.
    The relationship between this product and other asthma treatment drugs
    This product can be added to the patient's existing treatment plan.
    Reduce the dose of the combined drug:
    Bronchodilator
    In asthma patients who cannot be effectively controlled with bronchodilator alone, this product can be added to the treatment regimen. Once there is a clinical response (usually after the first dose), the dose of bronchodilator can be reduced according to the patient's tolerance. .
    Inhaled corticosteroids
    For patients with asthma who receive inhaled corticosteroids, the dose of glucocorticoids can be appropriately reduced according to the patient's tolerance. It should be gradually reduced under the guidance of a physician. Some patients can gradually reduce the amount until inhaled glucocorticoids are completely discontinued. However, this product should not be used to suddenly replace inhaled corticosteroids or as directed by your doctor.

    [Storage]
    Montelukast sodium tablets: stored at 15-30 ° C at room temperature, moisture and shading.
    Montelukast sodium chewable tablets: stored at 15-30 ° C at room temperature, moisture and shading.
    Montelukast sodium granules: sealed, protected from light, and stored at room temperature (15-30 ° C).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • pulmonary hypertension

    Ambesentan

    【Product name】Volibris, Letairis

    [English common name]Ambrisentan

    [Chinese common name]Alecic fumarate

    [English name]

    [Chinese other name]

    [indications]pulmonary hypertension.

    [Usage and Dosage] Adult (18 years old and above): 5~10 mg, once a day. Do not break, pry open or chew these pills. Children: Not recommended.

    [Storage]Store at 25 ° C (77 ° F); The allowable deviation is between 15 ° C and 30 ° C (59 ° F to 86 ° F).Store in original packaging.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Multiple sclerosis

    Dimethyl fumarate

    【Product name】TECFIDERA, dimethyl

    [English common name]Tecfidera

    [Chinese common name]Dimethyl fumarate

    [English name]Dimethyl ester, Dimethylfumarate

    [Chinese other name] moldKexing No. 1, anti-mold preservative

    [Indications] TECFIDERA is suitable for recurrenceMultiple sclerosisPatient treatment

    【Dosage】

    [Storage]Store at 15 ° C to 30 ° C (59 to 86 ° F).Protect capsules from light.Store in the original container.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Overactive bladder (OAB)

    Fexolid fumarate

    【Product name】Toviaz

    [English common name]Fesoterodine maleate

    [Chinese common name]Fexolid fumarate

    [English name]SPM 8272, SPM 907, (R)-Fesoterodine fumarate

    [Chinese other name]

    [indications]Overactive bladder.

    [Usage and Dosage] The recommended starting dose of Toviaz is 4 mg once a day. Swallow the tablet with a glass of water and do not chew it. Patients usually get the full effect of treatment after 2 to 8 weeks. Based on the individual response, the dose can be increased to 8 mg once a day. For patients with kidney or liver problems, the dose of Toviaz must be adjusted, or not at all, depending on whether they also receive 'CYP3A4 inhibitors', a group of drugs that may affect Toviaz's destruction in the body.

    [Storage] Do not store above 25 °C. Store in original packaging to protect it from moisture.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Chronic cellular leukemia (CML)

    Nilotinib

    【Product name】Tasigna, Dasina

    [English common name]Nilotinib

    [Chinese common name] nilotinib

    [English name]

    [Other names in Chinese] nilotinib

    [indications]
    Nilotinib: Philadelphia chromosome positive for resistance or intolerance to previous treatments (including imatinib)Chronic myeloid leukemia(Ph+ CML) Chronic or accelerated adult patients.
    Dasina (Nilotinib Capsule): Chronic or accelerated adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) who are resistant or intolerant to previous treatments (including imatinib).

    【Dosage】
    Nilotinib:
    The initial treatment of this product should be carried out under the guidance of a physician with experience in the treatment of CML patients.
    The definition of imatinib resistance is: imatinib failed to achieve complete hematologic remission for 3 months, failed to achieve cytogenetic remission after 6 months of treatment, or failed to achieve major cytogenetics after 12 months of treatment Relief, loss of complete hematologic remission or cytogenetic remission, disease progression, or emergence of resistant Bcr-Abl kinase mutations.
    The definition of imatinib intolerance is that, despite optimal supportive care, patients are discontinued with imatinib due to the persistence of grade 3 or 4 adverse events during any dose and/or treatment period; or Despite the use of optimal supportive care, grade 2 adverse events associated with imatinib therapy lasted for > 1 month, or more than 3 times, regardless of dose reduction or discontinuation of treatment.
    The recommended dose is 2 times daily, 400 mg each time, about 12 hours apart, at least 1 hour before meals or at least 2 hours after meals.
    As long as the patient continues to benefit, the treatment of this product should continue.
    Dasina (Nilotinib capsule): The initial treatment of this product should be carried out under the guidance of a physician with experience in treating CML patients.
    The definition of imatinib resistance is: imatinib failed to achieve complete hematologic remission for 3 months, failed to achieve cytogenetic remission after 6 months of treatment, or failed to achieve major cytogenetics after 12 months of treatment Relief, loss of complete hematologic remission or cytogenetic remission, disease progression, or emergence of resistant Bcr-Abl kinase mutations.
    The definition of imatinib intolerance is that, despite optimal supportive care, patients are discontinued with imatinib due to the persistence of grade 3 or 4 adverse events during any dose and/or treatment period; or Despite the use of optimal supportive care, grade 2 adverse events associated with imatinib therapy lasted for > 1 month, or more than 3 times, regardless of dose reduction or discontinuation of treatment.
    The recommended dose is 2 times daily, 400 mg each time, about 12 hours apart, at least 1 hour before meals or at least 2 hours after meals.
    As long as the patient continues to benefit, the treatment of this product should continue.
    Capsules should be swallowed with water and should not be chewed or sucked. Capsules should not be opened. Wash hands immediately after touching the capsules. Be careful not to inhale any powder in the capsule (such as capsule damage), and do not allow the powder to come into contact with skin or mucous membranes. If skin contact occurs, wash the area with soap and water. If the eyes are in contact with the powder, rinse with water. If the powder in the capsule is spilled, it should be wiped off with gloves and a disposable wet towel and placed in a sealed container for proper disposal.
    Dose adjustment: If the ECG shows QTc>480m, you should stop taking this product and check the serum potassium and magnesium in time. If the serum potassium and magnesium are lower than the normal limit, you should replenish it to the normal range, and you must check the merger. In the case of medication; if QTcF recovers to <450 milliseconds and does not differ from the baseline value by more than 20 milliseconds, the previous dose of the product can be restored within 2 weeks; if after 2 weeks, QTcF is between 450 and 480 milliseconds, then The dose of this product should be reduced to 400 mg once a day; if the QTcF is still > 480 milliseconds after reducing the dose to 400 mg per day, the product should be discontinued. Any 1 dose adjustment should be reviewed after 7 days.
    If hematological toxicity occurs (acceleration period: ANC < 0.5 × 109 / liter or platelet < 10 × 109 / liter; chronic phase: ANC < 1.0 × 109 / liter or platelet < 50 × 109 / liter), this product should be suspended Use, if the blood level of patients in the accelerated phase within 2 weeks recovers to ANC>1.0×109/liter or platelet>20×109/liter or above, or the blood level of patients in chronic phase recovers to ANC>1.0×109/liter or platelet>50×109/ If you are liter, you can take it again at the initial dose. If the blood picture is still low, consider reducing the dose of this product, taking it once a day, 400 mg each time.
    If there is moderate or severe non-hematologic toxicity with significant clinical significance, the drug should be discontinued; once the toxicity is relieved, the dose of 400 mg once a day can be restored. If clinically appropriate, consider increasing the dose to 400 mg twice daily.
    Elevated serum lipase: If 3-4 levels of serum lipase increase, the dose should be reduced to 400 mg once a day or discontinued. Serum lipase should be monitored monthly.
    Elevation of bilirubin and liver transaminases: If there is an increase in grade 3-4 bilirubin, the dose should be reduced to once a day, 400 mg each time or discontinued. Bilirubin and transaminase should be monitored monthly.
    *Special dose recommendation
    Children and adolescents: There are no clinical studies conducted in children or adolescents. Therefore, it is not recommended for the treatment of patients younger than 18 years old.
    Elderly patients: No special dose adjustments are required for patients over 65 years of age.
    Patients with renal insufficiency: There are no clinical studies in patients with renal insufficiency.
    Only a small part of this product and its metabolites are excreted by the kidneys, so patients with renal insufficiency are not expected to have a reduction in overall clearance. For patients with renal insufficiency, no dose adjustment is required.
    Patients with hepatic insufficiency: This product has not been studied in patients with hepatic insufficiency. Therefore, patients with hepatic insufficiency with a transaminase exceeding 2.5 times the normal value or 1.5 times higher than the normal value of bilirubin are not recommended for treatment.

    [Storage] Tasigna (nilotinib) capsules should be stored at 25 ° C (77 ° F); allowable deviation between 15 ° C and 30 ° C (59 ° F to 86 ° F).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Placeholder
    Malignant mesothelioma

    Chimeric immunoglobulin G-1-κ monoclonal antibody

    【Product name】

    [English common name]IgG1/κ monoclonal antibody

    [Chinese common name]Chimeric immunoglobulin G-1-κ monoclonal antibody

    [English name]

    [Chinese other name]

    [Indications] Muckle-Wells syndrome (MWS), neonatal multisystem inflammatory disease (NOMID)

    [Usage and Dosage] For patients with CAPS, the recommended starting dose of Ilaris is: adults, adolescents and children ≥ 4 years old: 150 mg body weight > 40 kg patients _2 mg / kg body weight ≥ 15 kg patients, ≤ 40 kg _ 4 mg / kg body weight ≥ 7.5 kg and <15kg children. 2 to <4 years old: 4 mg/kg for patients weighing ≥ 7.5 kg. Subcutaneous injections are administered once every 8 weeks. For patients with a starting dose of 150 mg or 2 mg/kg, if the clinical response is satisfactory (the rash and other systemic inflammations are resolved), the conservative treatment symptoms are still not achieved 7 days after the start of treatment, and can be considered at 150 mg or 2 mg/kg. The second dose of Ilaris. If a complete therapeutic response is subsequently reached, an intensive dosing regimen of 300 mg or 4 mg/kg every 8 weeks should be maintained. If a satisfactory clinical effect is not obtained after 7 days of increasing dose, the third dose of Ilarisi 300 mg or 4 mg/kg can be considered. If a complete treatment response is followed, maintain an intensive dosing regimen of 600 mg or 8 mg/kg. According to individual clinical judgment, 8 weeks should be considered. For patients with a starting dose of 4 mg/kg, 8 weeks should be considered if a satisfactory clinical response is not obtained. The second dose of Ilylis 4 mg/kg can be considered 7 days after the start of treatment. If completely treated. A response was subsequently obtained, maintaining a booster dose regime of 8 mg/kg

    [Storage]

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Solar keratosis (AK)

    Giant sterol ester

    【Product name】Picato

    [English common name]Ingenol

    [Chinese common name]Giant sterol ester

    [English name]

    [Chinese other name]

    [Indications] Gel is an indication forActinic keratosisLocal treatment for the induction of cell death.

    [Usage and Dosage] For topical use; not for oral, ocular, or intravaginal use.
    Avoid transferring Picato® to the periocular area.
    Avoid application near and around the mouth and lips.
    For a continuous area of up to one continuous area of the skin, use a unit dose tube of approximately 25 cm 2 (5 cm x 5 cm).
    Actinic keratosis in the face or scalp: Apply Picato® gel, 0.015% to the affected area once a day for 3 consecutive days.
    For the limbs or actinic keratosis: Apply Picato® gel, 0.05%, to the affected area once a day for 2 consecutive days.

    [Storage] Store Picato® gel in a 36oF – 46oF (2oC – 8oC) refrigerator; allow for offsets between 32oF – 59oF (0oC – 15oC). Prevent freezing.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Multiple myeloma , Acute leukemia

    mercaptopurine

    【Product name】Xaluprine, Purixan

    [English common name]Mercaptopurine

    [Chinese common name]mercaptopurine

    [English name]LEUKERIN

    [Chinese other name]Le Yunning

    [Indications] for chorionic epithelial cancer,Malignant mole,Acute lymphoblastic leukemiaAnd acute nonlymphocytic leukemia,Chronic myeloid leukemiaThe urgency period.

    【Dosage】
    Oral administration:
    Chorionic epithelial cancer: commonly used in adults, daily 6mg ~ 6.5mg / kg, divided into two oral, 10 days for a course of treatment, intermittent treatment for 3 to 4 weeks.
    leukemia:
    Start, daily 2.5mg / kg or 80 ~ 100mg / m2, once a day or in divided doses, generally 2 to 4 weeks after treatment can be markedly effective, such as 4 weeks after medication, no clinical improvement and white blood cell count , can be considered to be added to the daily 5mg / kg under careful observation;
    Maintain, daily 1.5mg ~ 2.5mg / kg or 50mg ~ 100mg / m2, once a day or divided into oral.

    [Storage] Closed light, sealed storage.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.